A detailed history of Livforsakringsbolaget Skandia, Omsesidigt transactions in Exelixis, Inc. stock. As of the latest transaction made, Livforsakringsbolaget Skandia, Omsesidigt holds 78,100 shares of EXEL stock, worth $3.44 Million. This represents 0.16% of its overall portfolio holdings.

Number of Shares
78,100
Previous 111,158 29.74%
Holding current value
$3.44 Million
Previous $4.9 Million 29.74%
% of portfolio
0.16%
Previous 0.01%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Jul 11, 2025

SELL
$34.13 - $46.26 $1.13 Million - $1.53 Million
-33,058 Reduced 29.74%
78,100 $3.44 Million
Q2 2025

Jul 09, 2025

BUY
$34.13 - $46.26 $3.79 Million - $5.14 Million
111,158 New
111,158 $4.9 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $14.2B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Livforsakringsbolaget Skandia, Omsesidigt Portfolio

Follow Livforsakringsbolaget Skandia, Omsesidigt and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Livforsakringsbolaget Skandia, Omsesidigt, based on Form 13F filings with the SEC.

News

Stay updated on Livforsakringsbolaget Skandia, Omsesidigt with notifications on news.